MAP Pharmaceuticals, Inc.NASDAQ
MAPP is defunct since March 4, 2013. acquired by a private company
  • Mar. 1, 2013, 3:18 PM

    Allergan (AGN +0.2%) shares tick higher after reporting the expiration of its tender offer to purchase all of the outstanding common shares of MAP Pharmaceuticals (MAPP) for $25 per share. The tender offer acquired about 75.1% of all outstanding shares, satisfying a majority. In order to complete a short-form merger, AGN says it will exercise a top-up option in which it will purchase newly issued shares in order to own one share more than 90% of shares outstanding. Separately, Wedbush cuts the shares to Neutral on the news.

    | Mar. 1, 2013, 3:18 PM
  • Jan. 22, 2013, 10:45 PM

    Allergan (AGN) agrees to acquire MAP Pharmaceuticals (MAPP) for $958M ($25/share) in cash, a 60% premium over MAP's Tuesday close. MAP's experimental migraine drug Levadex is set to receive a regulatory decision by April 15; Botox maker Allergan (which already had rights to help market Levadex) is showing confidence in an OK by taking total control.

    | Jan. 22, 2013, 10:45 PM | 1 Comment